Brief: Urogen Announces Start Of Pivotal Single-Arm Phase 3 Trial For UGN-102
03/02/2022 13:38
Feb 3 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN ANNOUNCES START OF PIVOTAL SINGLE-ARM PHASE 3 TRIAL
FOR
UGN-102, AN INVESTIGATIONAL NON-SURGICAL TREATMENT FOR LOW-GRADE
INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Source text for Eikon: ID:nBw3V8GK4a
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors